Boston Scientific's Promus Element Platinum Chromium Stent System Demonstrates Comparable Safety And Effectiveness Outcomes Versus Leading Drug-Eluting Stent In Platinum Workhorse Trial

Boston Scientific Corporation BSX today announced 12-month results from the pivotal PLATINUM Workhorse trial comparing the safety and effectiveness of the PROMUS Element™Everolimus-Eluting Platinum Chromium Coronary Stent System to the PROMUS® Everolimus-Eluting Coronary Stent System. The trial demonstrated the clinical non-inferiority of the PROMUS Element Stent in comparison to the PROMUS Stent in treating de novo coronary artery lesions while showing a procedural benefit of reduced rates of unplanned (bail-out or emergency) stenting.